Equity Research Database

Institutional Investment Pitches

Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.

Home Letters Funds Account

Alger Small Cap Focus Fund's investment thesis on FORTE BIOSCIENCES INC ($FBRX) — Q2 2026 | Buyside Digest

All Pitches

View Letter Analysis

$FBRXFORTE BIOSCIENCES INC

NEUTRAL

Alger Small Cap Focus Fund

Fund Letter

Q2 2026

Published July 17, 2026

View Fund Profile

$76.81USD

Current Market Price

Market Cap$1.6B

Pitch Price$76.99

Technical Chart

From the Fund Letter

Forte Biosciences is a clinical-stage biopharmaceutical company developing FB102, an anti-CD122 monoclonal antibody with potential application across a range of autoimmune conditions, including celiac disease, vitiligo, and alopecia areata. We view Forte...

— Amy Zhang

BSD Research Exclusive

Unlock Full Institutional Investment Theses

Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.

Institutional Pitch Library

Proprietary AI Analysis

100 Letter Unlocks/Quarter

SUBSCRIBE TO BSD RESEARCH Compare All Plans

Already a Research or Pro subscriber? Sign In

◆ Keep Reading

What other investors think about $FBRX, and what else Alger Small Cap Focus Fund is buying.

Other pitches on $FBRX

Other investors who've written on FORTE BIOSCIENCES INC

No other institutional pitches found for this ticker yet.

View all $FBRX pitches →